Archer Materials Limited (ASX:AXE) Enhances Biochip Feasibility and Advances Development Roadmap
Biochip Development Progress
Archer Materials has significantly improved the accuracy of potassium detection for its Biochip, intended for at-home testing of chronic kidney disease. The company has reduced on-chip device variability from 15% to 1.5%, enabling the next stage of development, which includes testing human blood samples and integrating the Biochip into a prototype cartridge system targeted for the end of 2025.
Regulatory and Clinical Plans
Archer is preparing to engage with regulatory bodies in the second half of 2025. Subject to regulatory feedback, the company expects to commence clinical trials for potassium detection using the Biochip in 2026. The engineering plans for calendar year 2025 include integrating the Biochip into a prototype cartridge system and demonstrating required potassium sensing accuracy with human blood samples.
Technical Developments
The company continues to bolster its intellectual property portfolio around the Biochip product by working closely with graphene foundry supplier Paragraf to improve gFET devices to meet the required sensing specifications.
Executive Comments
Greg English, Executive Chair of Archer, stated, “Over the past months, the Archer team has done a great job reducing the variability between gFETs on the same chip. This is a significant achievement in the development of the Biochip and allows us to progress to the next stage of development. The team is now looking towards testing human blood samples and integrating it into a prototype cartridge system. These are important steps before we engage in clinical trials.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.